HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

Harvard liver specialist suggests consuming 4 snacks weekly to reverse fatty liver GlaxoSmithKline Pharmaceuticals shares ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GlaxoSmithKline Pharmaceuticals' shares fell by 2% in Thursday's morning trade, reflecting a bearish market sentiment. The company is currently trading at Rs 2,680.10 per share.

In addition to Barclays, Sanofi also received a Buy from J.P. Morgan’s Richard Vosser in a report issued on August 8. However, on August 5, Deutsche Bank maintained a Hold rating on Sanofi (Other OTC: ...